 |
|
Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use
A Report of 3 Cases and Review of the Literature
Danny K. Chen, MD;
Joseph S. Kim, MD;
David M. C. Sutton, MD, FRCPC
Arch Intern Med. 1999;159:311-314.
Ticlopidine hydrochloride is an antiplatelet agent used for an increasing number of indications, including cerebrovascular disease, unstable angina, coronary artery stenting, and peripheral vascular bypass grafting. It has uncommon but severe hematologic effects, including thrombotic thrombocytopenic purpura. We report 3 new cases of ticlopidine-associated thrombotic thrombocytopenic purpura and review the English-language literature. Of the 13 patients described (10 from published articles), an equal number were women and men. The median age of the women was 50 years, and that of the men was 72 years. Thrombotic thrombocytopenic purpura occurred within 2 to 8 weeks of starting ticlopidine therapy. Survivors received plasma therapy, but of the 4 who died, 3 had received platelet transfusions. With discontinuation of the drug and prompt plasma exchange therapy, mortality was comparable to that seen with idiopathic thrombotic thrombocytopenic purpura, and relapse was uncommon. Physicians and patients should be aware of this potentially fatal but treatable complication of ticlopidine therapy.
From the Department of Medicine, Toronto Hospital, University of Toronto, Toronto, Ontario.
RELATED LETTER
Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use
Logan Elangovan
Arch Intern Med. 1999;159(14):1624.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Albers et al.
Chest 2008;133:630S-669S.
ABSTRACT
| FULL TEXT
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Albers et al.
Chest 2004;126:483S-512S.
ABSTRACT
| FULL TEXT
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Albers et al.
Chest 2001;119:300S-320S.
FULL TEXT
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality
Paradiso-Hardy et al.
CMAJ 2000;163:1441-1448.
ABSTRACT
| FULL TEXT
Spontaneous Reports of Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura From 2 Italian Regions
Venegoni et al.
Arch Intern Med 1999;159:2227-2228.
FULL TEXT
Thrombotic Thrombocytopenic Purpura Associated With Ticlopidine Use
Elangovan
Arch Intern Med 1999;159:1624-1624.
FULL TEXT
|
